News

Search:

FDA Says it Won't Approve Any Non-Abuse Resistant Oxycontin

1 Likes

In a long sought-after and potentially groundbreaking decision, the US Food and Drug Administration (FDA) has determined that generic non-abuse-resistant formulation of Purdue Pharma's drug Oxycontin Read More...

Tags:

Denied

FDA

Generic Oxycontin

oxycodone

OxyContin

Purdue Pharma

Drug Reformulations Lead to Shifting Patterns of Abuse

0 Likes

A report in the New England Journal of Medicine (NEJM) found abuse of a OxyContin, a branded version of the opioid oxycodone, went down significantly between 2010 and the first quarter of 2012 as the Read More...

Tags:

Abuse

drug

FDA

NEJM

Opana

Opioids

oxycodone

OxyContin

Pharmaceutical

Purdue Pharma

Senators Launch Investigation Into 'Dubious Marketing Practices' of Pain Pill Manufacturers

0 Likes

Explosive allegations have emerged from two prominent Senators regarding marketing tactics used by a number of pharmaceutical companies, including Purdue Pharma, Endo Pharmaceuticals and Johnson & Read More...

Tags:

American Pain Foundation

Baucus

Collusion

Congress

drug

Endo Pharmaceuticals

Grassley

Investigation

J&J

Johnson & Johnson

Letter

Pain

Pharmaceutical

Purdue Pharma

Senate

RF Today is Regulatory Focus' daily news brief. Each edition contains the top global regulatory news stories about pharmaceuticals, medical devices, biotechnology and more. Learn more

Most Viewed
Most Popular

Most Viewed

China's SFDA Becomes CFDA amidst Consolidation of Power and New Leadership 25 March 2013
FDA Plans Huge Cardiovascular Registry With Focus on Medical Devices 2 April 2013
In Unprecedented Shift, EU Parliament Proposes Premarket Authorization for Medical Devices 15 April 2013
Goodbye, KFDA: Korean Regulator Gets New Name, Decentralized Authority After Reorganization 28 March 2013
FDA Gets Go-Ahead for Study of DTC Advertising and Social Media 18 April 2013
UPDATED: President's Budget Proposal Calls for Small Increases at FDA, but Big Changes for Industry 11 April 2013
IBM Awarded Huge Contract to Modernize Regulatory Review Processes at FDA 29 April 2013
New FDA Document Clarifies IND Process for Drugs, Biologics and Biosimilars 30 April 2013

New Regulatory Focus Apps for iPad and iPhone

Stay Connected:

Regulatory Focus is for regulatory professionals written by regulatory professionals.

The publication takes a look at the important topics facing regulatory professionals in a changing global healthcare landscape. From topics ranging from research and development to labeling and marketing, the articles try to analyze, inform, and educate readers about the issues at the forefront of the industry.

Rated as the number one benefit by the members of RAPS, Regulatory Focus strives to provide the best and most current information to regulatory professionals so they can succeed and advance at every stage in their careers.

For questions or comments on our content or to find out more about Regulatory Focus, please visit our About RF page.

News

FDA Says it Won't Approve Any Non-Abuse Resistant Oxycontin

Drug Reformulations Lead to Shifting Patterns of Abuse

Senators Launch Investigation Into 'Dubious Marketing Practices' of Pain Pill Manufacturers

Get RF Today